News
· 1dNovo Nordisk’s Stock Price Soars Following Accelerated Approval of Wegovy for MASH and Liver Fibrosis
Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated significant improvements in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis compared to placebo at 72 weeks.
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...
MedPage Today on MSN1d
Semaglutide Gets FDA Greenlight for MASH
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
A Florence + The Machine album on Halloween just feels right. On Tuesday the band announced their new record Everybody Scream, debuting October 31. It was appropriately preceded by a teaser video ...
The Emmy-nominated Tramell Tillman immediately blew his whistle, with the band striking up the Powerman 5000 song “Relax,” ...
WFRV Green Bay on MSN1d
Beer lovers and soup fans unite for a Campbell’s and Pabst mash up
Soup and beer fans are getting a new mash-up this fall. Campbell’s Chunky is partnering with Pabst Blue Ribbon to launch two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback